BRL Medicine
Cell and Gene Therapy Drug Developer
Abbott
Provider of Health Diagnostic Products and Health Diagnostic Management Solutions
Simcere
Innovative Drug Developer
2026Year1Month8On [date], BRL Medicine officially announced the appointment of its core management team: Dr. Yu Xiang...2026Year1Month1CEO of the company (CEO), will comprehensively lead strategic planning, resource allocation, and overall operation management, assisting the company in achieving high-quality development during the critical phase of globalization, commercialization, and industrial upgrading, and accelerating the global clinical translation and market implementation of cutting-edge gene and cell therapy products.
Public information shows that Xiang Yu (Shawn Xiang) holds a bachelor's degree from Peking University and a Ph.D. from Yale University in the United States, with extensive experience in the pharmaceutical and healthcare fields.17Years of experience, with rich expertise in multinational enterprise management and local market operations.
His career began at McKinsey & Company in the United States, where he served as a management consulting advisor in the healthcare industry, focusing on pharmaceuticals and medical devices.
2011In that year, Xiang Yu joined Novartis's Swiss headquarters as the Global Pharmaceutical Strategy Director,2012Transferred to Novartis (China) since [Year], successively responsible for the management of respiratory and orthopedic businesses.
2016In that year, he joined Abbott's diabetes division as the regional general manager for Greater China and emerging Asian markets. He successfully facilitated the launch of multiple new products in key countries and built an ecosystem to serve diabetes patients.
Before joining Santen, Xiang Yu served as the CEO of Langyu Group, leading breakthroughs in the medical insurance access for several new rare disease drugs and establishing an ecosystem for rare disease patient services.
2024Year6Month3On [date], Xiang Yu officially assumed the position of Executive Director and President of China at Santen Pharmaceutical Co., Ltd. At the same time, he also serves as the Chairman and Manager of multiple affiliated companies, including Santen Pharmaceutical (China) Co., Ltd. and Santen Investment (China) Co., Ltd. He oversees the entire value chain operations in China, and is responsible for business strategy formulation, sales promotion, product portfolio management, and commercial excellence practices in the Chinese market. During this period, he has driven the release of...“Santen China 2.0Strategy”, Expanding business boundaries through multi-channel layout.
202511Month28Recently, Xiang Yu stepped down as President of Santen China and related positions.
